On June 27, 2025, Innovent Biologics, Inc., a leading biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for oncology, autoimmune, cardiovascular, and metabolic diseases, announced that China's National Medical Products Administration (NMPA) approved Mazdutide, the worlds first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity
Antihyperglycemic and antioxidant effects of a flavanone, naringenin, in streptozotocinnicotinamide-induced experimental diabetic rats
These improvements have been observed when the agents are used alone as well as in combination with PAP therapy, suggesting a complementary role for pharmacological and device-based approaches
As the prevalence of diabetes continues to rise, it is important to consider the potential diagnosis of LADA in patients with characteristics associated with this condition
doi: 10.1016/j.peptides.2013.07.015, 163 ZhengZ.ZongY.MaY.TianY.PangY.ZhangC.et al
For instance, federal health officials have launched a new program to make the current crop of weight-loss drugs available to older Medicare patients who are struggling with obesity
